Botulinum toxin treatment of secretory disorders
Identifieur interne :
000A84 ( PascalFrancis/Curation );
précédent :
000A83;
suivant :
000A85
Botulinum toxin treatment of secretory disorders
Auteurs : Markus Naumann [
Allemagne] ;
Wolfgang Jost [
Allemagne]
Source :
-
Movement disorders [ 0885-3185 ] ; 2004.
RBID : Pascal:04-0228841
Descripteurs français
English descriptors
Abstract
Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 19 |
---|
A06 | | | | @3 SUP8 |
---|
A08 | 01 | 1 | ENG | @1 Botulinum toxin treatment of secretory disorders |
---|
A09 | 01 | 1 | ENG | @1 Basic and Therapeutic Aspects of Neurotoxins |
---|
A11 | 01 | 1 | | @1 NAUMANN (Markus) |
---|
A11 | 02 | 1 | | @1 JOST (Wolfgang) |
---|
A12 | 01 | 1 | | @1 BIGALKE (HANS) @9 ed. |
---|
A12 | 02 | 1 | | @1 DRESSLER (Dirk) @9 ed. |
---|
A12 | 03 | 1 | | @1 JANKOVIC (Joseph) @9 ed. |
---|
A14 | 01 | | | @1 Department of Neurology, University of Würzburg @2 Würzburg @3 DEU @Z 1 aut. |
---|
A14 | 02 | | | @1 Department of Neurology, Deutsche Klinik für Diagnostik @2 Wiesbaden @3 DEU @Z 2 aut. |
---|
A15 | 01 | | | @1 Institute of Toxicology, Medical School of Hannover @2 Hannover @3 DEU @Z 1 aut. |
---|
A15 | 02 | | | @1 Department of Neurology, Rostock University @2 Rostock @3 DEU @Z 2 aut. |
---|
A15 | 03 | | | @1 Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 3 aut. |
---|
A20 | | | | @1 137-141 |
---|
A21 | | | | @1 2004 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000113591720190 |
---|
A44 | | | | @0 0000 @1 © 2004 INIST-CNRS. All rights reserved. |
---|
A45 | | | | @0 44 ref. |
---|
A47 | 01 | 1 | | @0 04-0228841 |
---|
A60 | | | | @1 P @2 C |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C01 | 01 | | ENG | @0 Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option. |
---|
C02 | 01 | X | | @0 002B17 |
---|
C03 | 01 | X | FRE | @0 Système nerveux pathologie @5 01 |
---|
C03 | 01 | X | ENG | @0 Nervous system diseases @5 01 |
---|
C03 | 01 | X | SPA | @0 Sistema nervioso patología @5 01 |
---|
C03 | 02 | X | FRE | @0 Bontoxilysin @2 FE @2 FR @5 02 |
---|
C03 | 02 | X | ENG | @0 Bontoxilysin @2 FE @2 FR @5 02 |
---|
C03 | 02 | X | SPA | @0 Bontoxilysin @2 FE @2 FR @5 02 |
---|
C03 | 03 | X | FRE | @0 Traitement @5 03 |
---|
C03 | 03 | X | ENG | @0 Treatment @5 03 |
---|
C03 | 03 | X | SPA | @0 Tratamiento @5 03 |
---|
C07 | 01 | X | FRE | @0 Metalloendopeptidases @2 FE |
---|
C07 | 01 | X | ENG | @0 Metalloendopeptidases @2 FE |
---|
C07 | 01 | X | SPA | @0 Metalloendopeptidases @2 FE |
---|
C07 | 02 | X | FRE | @0 Peptidases @2 FE |
---|
C07 | 02 | X | ENG | @0 Peptidases @2 FE |
---|
C07 | 02 | X | SPA | @0 Peptidases @2 FE |
---|
C07 | 03 | X | FRE | @0 Hydrolases @2 FE |
---|
C07 | 03 | X | ENG | @0 Hydrolases @2 FE |
---|
C07 | 03 | X | SPA | @0 Hydrolases @2 FE |
---|
C07 | 04 | X | FRE | @0 Enzyme @2 FE |
---|
C07 | 04 | X | ENG | @0 Enzyme @2 FE |
---|
C07 | 04 | X | SPA | @0 Enzima @2 FE |
---|
N21 | | | | @1 145 |
---|
N82 | | | | @1 OTO |
---|
|
pR |
A30 | 01 | 1 | ENG | @1 Toxins 2002. Conference @3 Hannover DEU @4 2002 |
---|
|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002237
Links to Exploration step
Pascal:04-0228841
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum toxin treatment of secretory disorders</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0228841</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0228841 INIST</idno>
<idno type="RBID">Pascal:04-0228841</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002237</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A84</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum toxin treatment of secretory disorders</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Bontoxilysin</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA06><s3>SUP8</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Botulinum toxin treatment of secretory disorders</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Basic and Therapeutic Aspects of Neurotoxins</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>NAUMANN (Markus)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JOST (Wolfgang)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>BIGALKE (HANS)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>DRESSLER (Dirk)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>JANKOVIC (Joseph)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Institute of Toxicology, Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA20><s1>137-141</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113591720190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0228841</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fN21><s1>145</s1>
</fN21>
<fN82><s1>OTO</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Toxins 2002. Conference</s1>
<s3>Hannover DEU</s3>
<s4>2002</s4>
</fA30>
</pR>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000A84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:04-0228841
|texte= Botulinum toxin treatment of secretory disorders
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | |